Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PRTC | US
1.04
5.39%
Healthcare
Biotechnology
30/06/2024
04/10/2024
20.33
19.70
20.33
19.64
PureTech Health plc a clinical stage biotherapeutics company engages in the discovery development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100 currently under Phase 3 stage to treat idiopathic pulmonary fibrosis (IPF); and LYT-200 a IgG4 monoclonal antibody currently under Phase 1/2 stage to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300 an oral allopregnanolone currently completed Phase 1 stage to treat depression anxiety and related indications; and LYT-310 an oral cannabidiol currently under preclinical stage to treat epilepsies and other neurological indications. In addition the company is developing LYT-503/IMB-150 a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis or bladder pain syndrome; and Glyph technology platform a lymphatic-targeting chemistry platform which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston Massachusetts.
View LessLow Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
51.9%1 month
61.8%3 months
60.4%6 months
55.9%-
-
1.61
0.30
0.16
-51.93
348.82
-
-134.73M
486.74M
486.74M
-
-23.05K
61.50
-90.90
-22.07
1.78
0.05
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
3.09
Range1M
4.55
Range3M
5.98
Rel. volume
0.60
Price X volume
123.81K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
UroGen Pharma Ltd | URGN | Biotechnology | 12.7 | 534.85M | 0.95% | n/a | 326.69% |
4D Molecular Therapeutics Inc | FDMT | Biotechnology | 9.97 | 518.14M | -2.92% | n/a | 2.32% |
Third Harmonic Bio Inc. | THRD | Biotechnology | 12.52 | 514.54M | -0.71% | n/a | 1.40% |
SIGA Technologies Inc | SIGA | Biotechnology | 6.98 | 498.16M | 0.87% | 5.95 | 0.97% |
CorMedix Inc | CRMD | Biotechnology | 8.9 | 497.15M | 7.62% | n/a | 1.29% |
Emergent BioSolutions Inc | EBS | Biotechnology | 9.35 | 494.68M | 1.74% | n/a | 226.97% |
KalVista Pharmaceuticals Inc | KALV | Biotechnology | 11.36 | 490.93M | -4.05% | n/a | 3.62% |
REGENXBIO Inc | RGNX | Biotechnology | 9.72 | 480.39M | -2.02% | n/a | 45.57% |
Anavex Life Sciences Corp | AVXL | Biotechnology | 5.595 | 474.43M | -1.06% | n/a | 0.00% |
OABI | OABI | Biotechnology | 3.99 | 471.47M | -1.97% | n/a | 8.27% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -51.93 | 0.76 | Cheaper |
Ent. to Revenue | 348.82 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 1.61 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 60.43 | 74.67 | Par |
Debt to Equity | 0.30 | -1.82 | Expensive |
Debt to Assets | 0.16 | 0.26 | Cheaper |
Market Cap | 486.74M | 3.73B | Emerging |